<p><b>TABLE OF INTERACTIONS WITH</b></p>

<p><b>ANDROGENS</b></p>

<p><b>From the French ANSM drug interactions document of September 2016, p. 16</b></p>

<table cellspacing="0" cellpadding="0" border="1">
<tbody>
<tr>
<td valign="top"><p><b>ANDROGENS</b></p>

<p><b>CLASS CODE: </b></p>

<p><b>A14AA0</b></p></td>
<td valign="top"><p><b>VITAMIN K ANTAGONISTS</b></p>

<p><b>CLASS CODE: </b></p>

<p><b>B01AA-001</b></p></td>
<td valign="top"><p>Increase of the risk of hemorrhage due to the direct effect on coagulation and/or the fibrinolytic systems.</p>

</td>
<td valign="top"><p><b>Precaution for use</b></p>

<p>More frequent testing of the INR. Adjustment of the dosage of the Vitamin K antagonist during the treatment with the androgen and after it is stopped. </p></td>
</tr>

<tr>
<td valign="top"><p><b>ANDROGENS</b></p>

<p><b>CLASS CODE: </b></p>

<p><b>A14AA0</b></p></td>
<td valign="top"><p><b>ENZYME INDUCERS</b></p>

<p><b>CLASS CODE: </b></p>

<p><b>N03-J05-001 </b></p></td>
<td valign="top"><p>Risk of decrease of the plasma concentrations of the androgen and consequently of its effectiveness, due to increase of its hepatic metabolism by the inducer</p></td>
<td valign="top"><p><b>Precaution for use</b></p>

<p>Clinical and biological monitoring during the administration of these substances together and 1 to 2 weeks after the inducer is stopped<b>. </b></p></td>
</tr>

</tbody>
</table>

